NCT00979563View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

November 30, 2010

Conditions
Advanced Solid Malignancies
Interventions
DRUG

HM30181AK tablet + Irinotecan tablets

HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT00979563 - Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter